Intraindividual comparison between
MRI
PSMA PET/CT
Prostate cancer
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
17
01
2020
accepted:
13
04
2020
pubmed:
29
4
2020
medline:
15
5
2021
entrez:
29
4
2020
Statut:
ppublish
Résumé
Accurate delineation of intraprostatic gross tumor volume (GTV) is mandatory for successful fusion biopsy guidance and focal therapy planning of prostate cancer (PCa). Multiparametric magnetic resonance imaging (mpMRI) is the current gold standard for GTV delineation; however, prostate-specific membrane antigen positron emission tomography (PSMA-PET) is emerging as a promising alternative. This study compares GTV delineation between mpMRI and One hundred one patients with biopsy-proven primary PCa who underwent mpMRI and In total mpMRI and MpMRI and
Identifiants
pubmed: 32342192
doi: 10.1007/s00259-020-04827-6
pii: 10.1007/s00259-020-04827-6
pmc: PMC7567709
doi:
Substances chimiques
Gallium Isotopes
0
Gallium Radioisotopes
0
Oligopeptides
0
gallium 68 PSMA-11
0
Edetic Acid
9G34HU7RV0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2796-2803Subventions
Organisme : Klaus Tschira Stiftung
ID : 00.014.2019
Références
Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1284-94
pubmed: 25975367
Theranostics. 2017 Jan 1;7(1):228-237
pubmed: 28042330
J Urol. 2016 Oct;196(4):1261-7
pubmed: 27220897
Radiat Oncol. 2018 Apr 12;13(1):65
pubmed: 29650029
Eur J Cancer. 2018 Nov;103:356-387
pubmed: 30100160
Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):62-9
pubmed: 17707266
Bioconjug Chem. 2012 Apr 18;23(4):688-97
pubmed: 22369515
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Eur Urol. 2019 May;75(5):712-720
pubmed: 30509763
Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):1076-1077
pubmed: 29445927
BJU Int. 2019 Sep;124(3):357-358
pubmed: 31436039
Eur Radiol. 2017 Dec;27(12):5290-5298
pubmed: 28608163
Radiother Oncol. 2019 Dec;141:208-213
pubmed: 31431386
J Nucl Med. 2015 May;56(5):668-74
pubmed: 25791990
Eur Urol. 2016 Nov;70(5):829-836
pubmed: 26795686
Theranostics. 2019 Apr 13;9(9):2595-2605
pubmed: 31131055
J Nucl Med. 2017 Nov;58(11):1805-1810
pubmed: 28473595
J Nucl Med. 2019 Jul;60(7):944-949
pubmed: 30552201
Sci Rep. 2019 Jul 24;9(1):10727
pubmed: 31341209
Abdom Imaging. 2015 Aug;40(6):1769-71
pubmed: 25412869
J Nucl Med. 2018 Jul 12;60(2):227-233
pubmed: 30002108
Prostate Cancer Prostatic Dis. 2018 Jun;21(2):204-211
pubmed: 29858591
Eur Urol. 2019 Sep;76(3):340-351
pubmed: 30898406
Diagn Interv Radiol. 2015 Sep-Oct;21(5):382-4
pubmed: 26200484
J Urol. 2017 Feb;197(2):320-326
pubmed: 27484386
Pharmaceuticals (Basel). 2014 Jun 30;7(7):779-96
pubmed: 24983957
Radiology. 2018 Dec;289(3):730-737
pubmed: 30226456
Histopathology. 2007 Mar;50(4):472-83
pubmed: 17448023
N Engl J Med. 2018 May 10;378(19):1767-1777
pubmed: 29552975
Radiology. 2018 Dec;289(3):738-739
pubmed: 30226450
Curr Opin Oncol. 2019 May;31(3):200-206
pubmed: 30865133
J Nucl Med. 2020 Apr;61(4):527-532
pubmed: 31562225
Radiother Oncol. 2019 Dec;141:214-219
pubmed: 31431366
Eur Urol. 2017 Apr;71(4):618-629
pubmed: 27568654
Prostate Int. 2019 Mar;7(1):1-8
pubmed: 30937291
JAMA Oncol. 2019 Jun 1;5(6):856-863
pubmed: 30920593
Eur J Nucl Med Mol Imaging. 2016 May;43(5):889-897
pubmed: 26592938